gamma-aminobutyric acid has been researched along with Diabetic Glomerulosclerosis in 9 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 7.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "Gabapentin (GBP) is a drug which is frequently used in diabetic neuropathy." | 5.35 | Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. ( Bilgir, F; Bilgir, O; Calan, M; Kebapçilar, L; Sari, I; Yildiz, Y; Yüksel, A, 2009) |
| "Rhabdomyolysis is an extremely rare side effect of GBP." | 5.35 | Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. ( Bilgir, F; Bilgir, O; Calan, M; Kebapçilar, L; Sari, I; Yildiz, Y; Yüksel, A, 2009) |
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 3.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| " With 2-L exchanges every 2 hours, we document an apparent elimination half-life of 41." | 1.46 | Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance. ( Edwards, JC; Ibrahim, H; Oman, Z; Schuelke, M, 2017) |
| "Gabapentin (GBP) is a drug which is frequently used in diabetic neuropathy." | 1.35 | Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. ( Bilgir, F; Bilgir, O; Calan, M; Kebapçilar, L; Sari, I; Yildiz, Y; Yüksel, A, 2009) |
| "Rhabdomyolysis is an extremely rare side effect of GBP." | 1.35 | Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. ( Bilgir, F; Bilgir, O; Calan, M; Kebapçilar, L; Sari, I; Yildiz, Y; Yüksel, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, H | 1 |
| Oman, Z | 1 |
| Schuelke, M | 1 |
| Edwards, JC | 1 |
| Sicras, A | 1 |
| Rejas, J | 1 |
| Navarro, R | 1 |
| Planas, A | 1 |
| Bilgir, O | 1 |
| Calan, M | 1 |
| Bilgir, F | 1 |
| Kebapçilar, L | 1 |
| Yüksel, A | 1 |
| Yildiz, Y | 1 |
| Sari, I | 1 |
| Chen, DT | 1 |
| Wynia, MK | 1 |
| Moloney, RM | 1 |
| Alexander, GC | 1 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Udall, M | 1 |
| Harnett, J | 1 |
| Mardekian, J | 1 |
| Hosseini-Zare, MS | 1 |
| Dashti-Khavidaki, S | 1 |
| Mahdavi-Mazdeh, M | 1 |
| Ahmadi, F | 1 |
| Akrami, S | 1 |
| Tesfaye, S | 1 |
| Selvarajah, D | 1 |
| Hayreh, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema[NCT02718547] | 25 participants (Anticipated) | Interventional | 2017-03-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for gamma-aminobutyric acid and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Diabetic Neuropathies; Fema | 2017 |
Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Drug Costs; Female; Gabape | 2013 |
Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy.
Topics: Amines; Anticonvulsants; Creatinine; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Dose-Respo | 2009 |
U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Data Collection; Diabetic Nephropathies; Drug Appro | 2009 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Databases, Factual; Diabetic Nephropathies; F | 2012 |
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.
Topics: Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Ne | 2012 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Drug Therapy, Combination; | 2005 |
Role of retinal hypoxia in diabetic macular edema: a new concept.
Topics: Adult; Blood Pressure; Diabetic Nephropathies; Diabetic Retinopathy; Female; Fluorescein Angiography | 2008 |